WEKO3
アイテム
M-SHRSPの高血圧性腎病変に対するカルシウム拮抗剤KW-3049の治療効果
https://kindai.repo.nii.ac.jp/records/2001643
https://kindai.repo.nii.ac.jp/records/20016437f41fc03-cf16-493d-bda6-180566329a76
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AN00063584-19941230-0081.pdf
|
|
| Item type | ☆紀要論文 / Departmental Bulletin Paper(1) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-07-26 | |||||||||||||||||
| タイトル | ||||||||||||||||||
| タイトル | M-SHRSPの高血圧性腎病変に対するカルシウム拮抗剤KW-3049の治療効果 | |||||||||||||||||
| 言語 | ja | |||||||||||||||||
| タイトル | ||||||||||||||||||
| タイトル | Therapeutic effects of a calcium antagonist (KW-3049) on renal changes in M-SHRSP | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| 著者 |
太田, 善夫
× 太田, 善夫
× 前西, 修
× 鈴木, 庸之
|
|||||||||||||||||
| 言語 | ||||||||||||||||||
| 言語 | jpn | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 主題 | KW-3049, malignant hypertension, M-SHRSP, renal function | |||||||||||||||||
| 資源タイプ | ||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||||||||
| 版 | ||||||||||||||||||
| 出版タイプ | AM | |||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||||||
| 出版者 名前 | ||||||||||||||||||
| 出版者 | 近畿大学医学会 | |||||||||||||||||
| 言語 | ja | |||||||||||||||||
| 書誌情報 |
ja : 近畿大学医学雑誌 en : Medical Journal of Kinki University 巻 19, 号 4補冊, p. 81-86, 発行日 1994-12-30 |
|||||||||||||||||
| ISSN | ||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||
| 収録物識別子 | 03858367 | |||||||||||||||||
| 内容記述 | ||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||
| 内容記述 | It has been reported that calcium antagonists have the potential to protect kidneys from hypertension. However, the therapeutic effect of calcium antagonists on kidneys (especially in malignant hypertension) is not quite clear. Using M-SHRSP, this pathological and biochemical study was performed to evaluate the renal effect of a calcium antagonist in malignant hypertension. Eleven-week-old male M-SHRSP were used. A calcium antagonist (KW-3049) was administered orally at daily dosages of 10 mg or 20 mg/kg/day via catheter. The treatment continued for five weeks. Excretion of urinary albumin and glucose, serum concentrations of creatinine (CRE), blood urea nitrogen (BUN), albumin (ALB), and glucose (GLU) were measured. For control group rats, the blood pressures were over 250 mmHg and the urinary excretions of albumin and glucose were abundant, and serum albumin concentrations and creatinine clearances (CCR) were low while BUN concentrations were high. However, in both treatment groups, blood pressure decreased to less than 150 mmHg within 6 hours following administration, but then increased gradually to more than 250 mmHg by 24 hours after the administration. Urinary excretions of albumin and glucose were significantly less than those of the control rats. Levels of serum albumin, CCR and BUN were within normal ranges. Pathological results showed that control rats had high frequencies of hypertensive vascular lesions with degenerated and/or atrophic urinary tubules and glomerulus collapse. However, in both treatment groups, the incidence of such hypertensive lesions was much lower than that of the control rats. These findings suggest that KW-3049 may be advantageous for kidney hypertensive vascular lesions and for repairing and/or protecting renal structures and functions. | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| 内容記述 | ||||||||||||||||||
| 内容記述タイプ | Other | |||||||||||||||||
| 内容記述 | 本文データはCiNiiから複製したものである。 | |||||||||||||||||
| 言語 | ja | |||||||||||||||||
